Michelson Medical Research Foundation, Inc.
Long book
$98.5M
Q1 2026
Positions
21
Top-10 weight
73%
concentration
Last quarter
+18.2%
SPY +14.8%
Turnover
22%
of book per quarter
Strategy in plain words
auto-generated from filingsMichelson Medical Research Foundation, Inc. is a wealth-management firm allocating client money, running a $98.5M US long book across 21 positions.
The portfolio is concentrated: the top 10 names carry 73% of the portfolio. Turnover is modest: positions are typically held for years. Current anchor positions: VAIL RESORTS INC, ISHARES S&P 500 VALUE ETF, VANGUARD FTSE DEVELOPED ETF, UNITEDHEALTH GROUP INC, VANGUARD FTSE EMERGING MARKE.
Over the last 9 quarters its long book ran on average 0.6pp per quarter ahead of the S&P 500, beating the index in 6 of 9 quarters. Its holdings are mechanical (indexing / client flows), so position changes carry no stock-picking signal.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-0.4%
Q2 2024
+9.0%
Q3 2024
-3.9%
Q4 2024
-2.2%
Q1 2025
+7.6%
Q2 2025
+10.6%
Q3 2025
+5.4%
Q4 2025
+1.6%
Q1 2026
+18.2%
Sector allocation
Services media 48%
Financials 24%
Consumer discretionary 16%
Energy 6%
Other 6%
Long book by quarter
What does Michelson Medical own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| MTN VAIL RESORTS INC | Services media | 86.0K | $11.0M | 11.2% | Held |
| UNH UNITEDHEALTH GROUP INC | Financials | 30.0K | $8.1M | 8.2% | Held |
| CNNE CANNAE HOLDINGS INC | Consumer discretionary | 480.6K | $5.5M | 5.5% | New |
| MANU MANCHESTER UNITED PLC-CL A | Services media | 200.0K | $3.4M | 3.4% | Held |
| CRGY CRESCENT ENERGY INC-A | Energy | 156.2K | $2.1M | 2.1% | Held |
| BATRK ATLANTA BRAVES HOLDINGS IN-C | Services media | 45.1K | $1.9M | 2.0% | New |
| OCSL OAKTREE SPECIALTY LENDING CO | — | 170.1K | $1.9M | 2.0% | New |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 21 | $98.5M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 20 | $99.8M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 20 | $115.0M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 20 | $104.2M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 25 | $119.5M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 28 | $119.3M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 28 | $141.9M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 25 | $116.3M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 28 | $165.0M | canonical | SEC ↗ |